Skip to main content
OpenTrials
Completed

NCT Number: NCT01395602

Effect of Cabergoline on Weight and Glucose Tolerance

The aim of this study is to determine the efficacy of cabergoline, a long-acting dopamine receptor agonist, on body weight and blood glucose in healthy obese adults.

This is a randomized double-blind placebo controlled study. Twenty subjects each will be randomly assigned either placebo or cabergoline for 16 weeks.

The effect of treatment on body weight and blood glucose and insulin levels will be compared in the treatment versus the placebo arm.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Body Weight Impaired Glucose Tolerance in Obese Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Columbia University

New York, 10032, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age 18 - 55 years
  • BMI 30 -40

Exclusion criteria

  • diabetes,
  • clinically significant medical condition,
  • use of medications that effect blood glucose or body weight

Treatment and study plan

cabergoline

Drug

cabergoline 0.5 mg twice weekly

Placebo

Other

1 pill twice weekly

Primary outcomes

  1. body weight

    Time frame: 16 weeks

Secondary outcomes

  1. glucose

    Time frame: 16 weeks

Sponsors and collaborators

Lead sponsor

Columbia University

Other

Registry information

Official study title

Randomized Controlled Pilot Study of the Effect of Cabergoline on Body Weight and Glucose Tolerance in Healthy Obese Adults

Important dates

Study start
2002
Primary completion
2003
Study completion
2011
First posted
Jul 15, 2011
Registry last updated
Oct 14, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.